CJC-1295 No DAC

CJC-1295 without DAC (also known as Mod GRF 1-29) is a 29-amino acid analog of growth hormone releasing hormone. The modifications (Tyr substituted for His, D-Ala, Gln, Ala, and Nle at positions 1, 2, 8, 15, and 27) enhance receptor binding affinity but result in a short half-life (~30 minutes) due to rapid enzymatic degradation.

PubMed results: 0 · Human studies: 0 · Animal studies: 0

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Based on limited human pharmacokinetic data

• Subcutaneous Injection — standard range 100-200 mcg, 1-3 times daily. Short half-life requires multiple daily dosing

~30 minutes (moderate confidence)

• Pulsatile growth hormone release (Limited): CJC-1295 without DAC (Mod GRF 1-29) is researched as a short-acting GHRH analog that stimulates pituitary GH release with a ~30-minute half-life, more aligned with physiologic pulse timing than long-acting DAC forms
• Enhanced GHRH receptor affinity via sequence modifications (Strong preclinical): Amino acid substitutions (including D-Ala and related modifications at key positions) were designed to improve receptor binding affinity relative to native GHRH 1-29 while remaining subject to rapid enzymatic degradation
• Synergy research with GH secretagogues (Limited): Research and experimental protocols often study short-acting GHRH analogs alongside ghrelin-receptor agonists because the pathways can act cooperatively on GH release

• Flushing or transient warmth — Mild, Anecdotal. Anecdotal reports around short-acting GHRH analogs include transient flushing; published formal safety datasets for Mod GRF 1-29 remain limited
• Injection site reactions — Mild, Anecdotal. Local injection-site reactions are reported anecdotally with subcutaneous peptide research use

• Active malignancy (Theoretical / Preclinical): Stimulation of the GH/IGF-1 axis raises theoretical concern in active cancer research contexts
• Uncontrolled diabetes or significant hyperglycemia risk (Theoretical / Preclinical): GH-axis stimulation can affect glucose handling; research literature commonly flags metabolic caution when studying GHRH analogs

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water